Navigation Links
MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Date:3/11/2008

Thursday, March 13, 2008 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, March 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, March 13, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third fiscal quarter ended January 31, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MIGENIX releases CEO message #22
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
4. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
5. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
8. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. NeoStem to Present at Third Annual Stem Cell Summit in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the “hairy ... a depiction of a system of linkages and connections so complex and dense ... of computer science at Worcester Polytechnic Institute (WPI) and director of the university’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Market with the addition of its newest module, US Hemostats & Sealants. , ... thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):